Adare Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Adare Pharmaceuticals, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 4 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include A, LB, ADARE, ADVATAB, and PARVULET. The owner is based in Philadelphia, PA.
7722 Dungan Road
Philadelphia, PA 19111
Showing of trademarks Trademarks
Trademark Classifications
Adare Pharmaceuticals, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Adare Pharmaceuticals, Inc. have?
Adare Pharmaceuticals, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 cancelled.
What trademark classes does Adare Pharmaceuticals, Inc. file in?
Adare Pharmaceuticals, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 40 (Treatment & Processing), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Adare Pharmaceuticals, Inc.'s most well-known trademarks?
Adare Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as A, LB, ADARE, ADVATAB, and PARVULET. These are among 7 currently registered trademarks in the portfolio.
What is Adare Pharmaceuticals, Inc.'s trademark registration success rate?
Adare Pharmaceuticals, Inc. has a 88% trademark registration rate, with 7 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.